95% confidence interval [CI], 1.70 to 2.36) and heart failure with reduced ejection fraction (HFrEF) (HR, 1.60
Its the ones that are taken over a shorter period that can cause the most trouble
First, cessation of GLP-1 treatment is associated with marked weight regain, as highlighted in a recent meta-analysis of eight randomised controlled trials which reported that participants taking semaglutide/tirzepatide regained 9.69 kg (95% CI 5.78, 13.60) over 4852 weeks [4]
While semaglutide medication can be effective (but has side effects), it doesnt address why your natural GLP-1 system may no longer be working as it should
Animal studies have shown thyroid C-cell tumours with some GLP-1 receptor agonists, though human relevance remains uncertain
268,272 Improving Long-Term Adherence While persistent GLP-1 therapy is recommended for obesity control and weight maintenance, most individuals prescribed GLP-1s for obesity treatment stop taking the drug within 1 year